| dc.contributor.author | Yerlioğlu, Dilay | |
| dc.date.accessioned | 2021-03-05T16:27:15Z | |
| dc.date.available | 2021-03-05T16:27:15Z | |
| dc.identifier.citation | Yerlioğlu D., "Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on Adalimumab", ESPGHAN 52nd Annual Meeting, Glasgow, İskoçya, 5 - 08 Haziran 2019, ss.117 | |
| dc.identifier.other | av_c0b5633c-e45f-41fa-b7dc-a1a7ba1da0f1 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/127915 | |
| dc.identifier.uri | https://www.espghancongress.org/fileadmin/user_upload/downloads/Scientific_Programme/ESPGHAN2019_Programme_Book.pdf | |
| dc.description.abstract | Treat to target strategy has been proposed in adult IBD to improve Quality of Life, symptoms and to treat inflammation. There are little data in the paediatric population for this approach. The aim of this study was to look if set goals (reduced PCDAI/PUCAI and Mayo/SES-CD) were achieved. | |
| dc.language.iso | eng | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Klinik Tıp (MED) | |
| dc.title | Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on Adalimumab | |
| dc.type | Bildiri | |
| dc.contributor.department | İstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü | |
| dc.contributor.firstauthorID | 2259193 | |
